Inhibition of VEGFR‐2 using axitinib also showed activity in a phase II trial in patients with metastatic melanoma 15 and the anti‐VEGF antibody bevacizumab enhanced the activity of cytotoxic chemotherapy in a randomized phase II trial 16, particularly in patients with M1c disease especially with elevated LDH. Here, KDR is linked to metastatic melanoma.